| RRC ID |
67179
|
| 著者 |
Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K, Ohkawara T, Fujimoto M, Kishimoto T, Kimura T, Naka T.
|
| タイトル |
Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.
|
| ジャーナル |
Mol Cancer Ther
|
| Abstract |
Ovarian cancer is the leading cause of gynecologic cancer-related deaths and novel therapeutic strategies are required. Programmed cell death 1 and programmed cell death ligand 1 (PD-L1), which are key mediators of host immune tolerance, are associated with ovarian cancer progression. Recent evidence indicates the importance of IFNγ-induced PD-L1 for immune tolerance in ovarian cancer. This study aimed to reveal the therapeutic potential of suppressor of cytokine signaling 1 (SOCS-1), an endogenous inhibitor of the Janus kinase (JAK)-STAT signaling pathway, for the treatment of ovarian cancer. IHC assessment revealed that patients with ovarian cancer with high intratumoral STAT1 activation exhibited poor prognosis compared with patients with low STAT1 activation (P < 0.05). Stimulation of OVISE, OVTOKO, OV2944-HM-1 (HM-1), and CT26 cell lines with IFNγ induced STAT1 phosphorylation and PD-L1 expression. Adenovirus-mediated SOCS-1 gene delivery (AdSOCS-1) in HM-1 and CT26 cells in vitro potently inhibited IFNγ-induced STAT1 phosphorylation and PD-L1 upregulation, similar to the addition of JAK inhibitor I, but failed to inhibit their proliferation. Notably, intratumoral injection of AdSOCS-1, but not AdLacZ, significantly inhibited the tumor growth of HM-1 and CT26 cells subcutaneously transplanted in immunocompetent syngeneic mice. AdSOCS-1 reduced PD-L1 expression on tumors and restored the activation of tumor-infiltrating CD8+ T cells. Moreover, the antitumor effect of AdSOCS-1 was significantly attenuated by PD-L1 Fc-fusion protein administration in vivo, suggesting that the effect of AdSOCS-1 is mainly attributable to enhancement of tumor immunity. This study highlights the potential clinical utility of SOCS-1 as an immune checkpoint inhibitor. Mol Cancer Ther; 17(9); 1941-50. ©2018 AACR.
|
| 巻・号 |
17(9)
|
| ページ |
1941-1950
|
| 公開日 |
2018-9-1
|
| DOI |
10.1158/1535-7163.MCT-17-0822
|
| PII |
1535-7163.MCT-17-0822
|
| PMID |
29891489
|
| MeSH |
Adenoviridae / genetics
Animals
B7-H1 Antigen / genetics
B7-H1 Antigen / immunology*
B7-H1 Antigen / metabolism
Cell Line, Tumor
Female
Gene Expression Regulation, Neoplastic / immunology*
Genetic Therapy / methods
Genetic Vectors / genetics
Humans
Mice
Ovarian Neoplasms / genetics
Ovarian Neoplasms / immunology*
Ovarian Neoplasms / therapy
Suppressor of Cytokine Signaling 1 Protein / genetics
Suppressor of Cytokine Signaling 1 Protein / immunology*
Suppressor of Cytokine Signaling 1 Protein / metabolism
T-Lymphocytes / immunology*
T-Lymphocytes / metabolism
Transplantation, Homologous
|
| IF |
5.615
|
| リソース情報 |
| ヒト・動物細胞 |
OV2944-HM-1(RCB1483) |
